These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33446239)

  • 1. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
    Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
    J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X; Gao X; Yang Y; Yang D; Guo Q; Li L; Liu S; Cong W; Lu S; Hou L; Wang B; Li N
    Apoptosis; 2024 Aug; 29(7-8):1161-1184. PubMed ID: 38743191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
    Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
    Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC.
    Wang S; Cheng H; Li M; Gao D; Wu H; Zhang S; Huang Y; Guo K
    Cell Death Dis; 2024 Jul; 15(7):484. PubMed ID: 38969639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
    Li C; Chen X; Wu J; Heng S; Xu Z; Gu H; Lin E; Wang J; Shan Y
    Biochem Biophys Res Commun; 2024 Nov; 734():150782. PubMed ID: 39378786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting Pink1/Parkin-mediated mitophagy enhances the anticancer effects of quercetin in hepatocellular carcinomaf.
    Chen F
    Biochem Biophys Res Commun; 2024 Jun; 712-713():149899. PubMed ID: 38653003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.
    Hao J; Peng Q; Wang K; Yu G; Pan Y; Du X; Hu N; Zhang X; Qin Y; Li H
    Biomed Res Int; 2021; 2021():6613439. PubMed ID: 34337035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMX2 potentiates cell viability of hepatocellular carcinoma by promoting autophagy and mitophagy.
    Zhang W; Tang Y; Yang P; Chen Y; Xu Z; Qi C; Huang H; Liu R; Qin H; Ke H; Huang C; Xu F; Pang P; Zhao Z; Shan H; Xiao F
    Autophagy; 2024 Oct; 20(10):2146-2163. PubMed ID: 38797513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K; Yamada M; Morishita A; Ono M; Himoto T; Kobara H; Masaki T
    Biochem Pharmacol; 2024 Aug; 226():116321. PubMed ID: 38815631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway.
    Zhu W; Li W; Geng Q; Wang X; Sun W; Jiang H; Pu X
    Med Sci Monit; 2018 Oct; 24():7625-7632. PubMed ID: 30359340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.
    Wu Z; Wang J
    Discov Med; 2024 Jan; 36(180):199-208. PubMed ID: 38273760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation.
    Qin C; Wang Y; Zhao B; Li Z; Li T; Yang X; Zhao Y; Wang W
    Cell Death Dis; 2023 Mar; 14(3):191. PubMed ID: 36906621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
    Xie P; Wu M; Wang H; Zhang B; Zhang Z; Yan J; Yu M; Yu Q; Zhao Y; Huang D; Xu M; Xu W; Li H; Xu Y; Xiao Y; Guo L
    Oncogene; 2024 Oct; 43(42):3108-3120. PubMed ID: 39251847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.